Vivet Therapeutics

Vivet Therapeutics is a biotechnology startup that specializes in developing gene therapies for rare, inherited metabolic diseases. The company's primary focus is on liver-directed AAV (Adeno-Associated Virus) products, which are used to deliver healthy genes to replace defective ones in patients with specific genetic disorders.

The company's key products are VTX-802, VTX-803, and VTX-804, all of which are currently under preclinical testing. VTX-802 and VTX-803 are designed for patients with Progressive Familial Intrahepatic Cholestasis Types 2 and 3, respectively. These are rare genetic disorders that cause progressive liver disease. The therapies work by delivering a healthy version of a specific gene to the liver. VTX-803 has received Orphan Drug Designation in the US and EU, which provides certain benefits for drugs intended for the treatment of rare diseases. VTX-804 is for patients with Citrullinemia Type 1, a rare inherited disorder that causes ammonia and other toxic substances to accumulate in the blood.

Vivet also has two technology platforms under development, VTX-PSM and VTX-PID. VTX-PSM is a non-integrative viral-based technology that allows for sustainable expression in growing organs and tissues. VTX-PID is aimed at reducing Neutralizing Antibodies levels, which can interfere with the efficacy of gene therapies.

Vivet Therapeutics operates in the biotechnology and healthcare markets, serving patients with rare genetic disorders. The company's business model is based on the development and commercialization of its gene therapies. It generates revenue through the sale of these therapies once they have been approved for use. The company is backed by a strong team of experienced scientists and investors from both sides of the Atlantic.

Keywords: Biotechnology, Gene Therapy, Liver-Directed AAV Products, Rare Genetic Disorders, Progressive Familial Intrahepatic Cholestasis, Citrullinemia Type 1, Preclinical Testing, Orphan Drug Designation, Neutralizing Antibodies, Investors.